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A 49-year-old male with known history of end-stage renal disease (ESRD) presents with an intraoral exophytic mass of the right
mandible. This lesion was given a histologic diagnosis of a Brown tumor. Purpose. To allow physicians to include this lesion in a
diﬀerential diagnosis when evaluating patients with primary, secondary, or tertiary hyperparathyroidism.
1.Introduction
Hyperparathyroidism (HPT), the overproduction of para-
thyroid hormones, results in an increased release of cal-
cium from bone which directly aﬀects the skeletal system.
Calcium’s concentration in plasma is increased and its
absorption by the kidneys and intestine is altered. This
leads to skeletal demineralization and allows for bone to
be replaced by multinucleated giant cells believed to be
osteoclasts weakening the skeletal structure [1].
Primary HPT is caused by hypersecretion of the parathy-
roid hormone (PTH), usually due to hyperplastic or tumoral
changes of one of the four parathyroid glands. The result is
hypercalcemia. Secondary HPT is usually due to end-stage
renal disease (ESRD). There is renal loss of calcium, and
with normal parathyroid glands, elevation of PTH occurs
in response to the hypocalcemia. Tertiary HPT appears in
patients with longstanding secondary disease, as hyperplasia
of parathyroid glands and loss of response to the level of
calcium in serum [2].
The hallmark of PTH excess is increased osteoclastic
activity with bone resorption. Cortical and trabecular bone
are lost and replaced by loose connective tissue. In some
instances, collections of osteoclasts, reactive giant cells, and
hemorrhagic debris form a distinct mass, termed a brown
tumor of hyperparathyroidism [3].
2.CaseReport
A 49-year-old African American male presents with a chief
complaint of right mandibular pain, edema, and intraoral
bleeding at night. This condition has persisted for 12 months
with a gradual increase in size and pain. This patient
has medical history signiﬁcant for ESRD, for which he
undergoes dialysis three times per week for the past 10 years,
congestive heart failure, anemia, diabetes mellitus, and atrial
ﬁbrillation. He has been prescribed oral calcium and vitamin
D supplements which he has not been compliant with.
Extraoral examination reveals facial asymmetry with
right facial enlargement (Figure 1) which is soft to palpation
and mildly tender, no trigeminal nerve paresthesia was
noted. Intraoral examination shows a large soft tissue mass
measuring 8cm × 2cm × 4cm extending from right
mandibular second premolar to 2cm past right mandibular
third molar (Figure 2). There was no buccal or lingual
expansion of bone noted clinically. The ﬁrst molar was
mobile and the second and third molars were free ﬂoating
lingually in the soft tissue mass. Bleeding and pain were
noted upon palpation of mass and associated teeth.
Panoramic radiograph shows a well-deﬁned multilocular
radiolucent lesion in the right mandibular body. This lesion
extends from one centimeter posterior to the third molar to
the second premolar in a horizontal dimension and from2 Case Reports in Radiology
Figure 1: Extraoral presentation.
Figure 2: Intraoral expansion of the mandible.
the inferior border of the mandible to the alveolar ridge
in a vertical dimension. The mandibular second and third
molars are displaced and the inferior alveolar nerve canal is
obliterated (Figure 3).
With clinical and radiographic diagnosis of brown
tumor versus odontogenic tumor, an incisional biopsy was
performed and a specimen from the central area of the soft
tissuemassmeasuring1.2cm × 0.6cm × 0.5cmandsentto
pathology in formalin. H&E stain showed numerous multi-
nucleated giant cells in a hypercellular ﬁbrous background
with hemosiderin pigmentation. A histological diagnosis of
brown tumor of hyperparathyroidism was rendered.
3. Discussion
ESRD refers to bilateral, progressive, chronic deterioration
of nephrons, the functional unit of the kidney. The disease
results in uremia and can lead to death [4]. Decreased
glomerular ﬁltration occurs with reduced nephron function,
Figure 3: Panoramic radiography showing a multilocular radiolu-
cency of the right mandible.
which results in decreased 1,25-dihydroxyvitamin D synthe-
sis by the kidney leading to decreased calcium absorption by
the gut. Consequently an increased level of serum phosphate
is also seen. Phosphate is the driving force of bone miner-
alization, excess phosphate tends to cause serum calcium to
be deposited in bone, leading to a decreased serum calcium
level and structurally deﬁcient bones. In response to low
serum calcium, the parathyroid glands are stimulated to
secretePTH,whichresultsinsecondaryHPT[4].Thepatient
becomes hypocalcemic and hyperphosphatemic, opposite of
primary HPT [5].
A variety of bone disorders are seen in ESRD; these are
collectively referred to as renal osteodystrophy [4]. In some
cases like the present one, HPT is diagnosed by the presence
of osteolytic lesions called brown tumors. Only about one in
ﬁve patients with HPT has radiographically observable bone
changes. The major manifestations of HPT are as follows.
(1) Subtle erosions of bone from the subperiosteal
surfaces of the phalanges of the hands.
(2) Demineralization of the skeleton resulting in an
unusual radiolucent appearance.
(3) Osteitis ﬁbrosa cystica in localized regions of bone
loss produced by osteoclastic activity, resulting in a
loss of all apparent bone structure.
(4) Brown tumors which occur late in the disease and in
about 10% of cases.
(5) Pathologic calciﬁcations in soft tissues that have a
punctate or nodular appearance and occur in the
kidneys and joints.
(6) In prominent HPT the entire calvarium has a granu-
larappearancecausedbythelossofcentraltrabeculae
and thinning of the cortical tables [6].
Brown tumors are caused by alterations in the trabec-
ular bone pattern, demineralization, and replacement by
loose connective tissue. They present as uni/multilocular
radiolucencies, and/or mixed lesions with bone expansion,
bone deformity, tooth mobility, and loss of lamina dura
[7]. The radiographic manifestations are in many cases
incidental ﬁndings and may be multiple. Demineralization
andthinningofcorticalboundariesoftenoccurinthejawsin
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canal, and the cortical outlines of the maxillary sinuses. The
density of the jaws is decreased, resulting in a radiolucent
appearance that contrasts with the density of the teeth. The
teeth stand out in contrast to the radiolucent jaws. A change
in the normal trabecular pattern may occur, resulting in
a ground-glass appearance of numerous, small, randomly
oriented trabeculae [6].
HistologicallyBrowntumorofHPTissimilartogiantcell
tumor: multinucleated giant cells in a background of spindle
cell proliferation containing a large amount of hemosiderin
[3, 8, 9].
The best diagnostic method for secondary HPT is para-
thyroid immunoassay and conﬁrmation of ESRD. Further
workupwithosseousscintigraphy(usingtechnetium99m—
methylene diphosphonate) may be indicated to locate other
areas of osseous metabolic disease as discussed by Prado et
al. [10].
The treatment of a Brown tumor is mainly pharmalogic
by treating the underlying HPT; however, surgical excision is
sometimes necessary. Triantaﬁllidou et al. advocate curettage
ofthelesionandwoundpackingallowingforsecondaryheal-
ing in addition to adjunctive treatment of underlying disease
[11]. HPT is commonly treated with calcium, vitamin D,
and controlled dialysis, although renal transplant or subtotal
parathyroidectomy may also be options. Since bone healing
in these patients is compromised, HPT must be controlled
prior to successful surgical bone reconstruction [5, 12].
4. Conclusion
ESRD is a worldwide problem that continues to increase;
these patients may have many serious medical problems,
and physicians must know how to manage them [13].
ESRD can lead to HPT, which has several manifestations
that can be seen in clinical and radiographic exams. The
physician should be aware of the clinical manifestations and
radiographic appearances of these lesions to allow for early
treatment of the underlying diseases and improvement of
overall prognosis.
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